Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

- Company Advancing Lead Candidate HspE7 into Phase 2 Clinical Trial in

2008 -

SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today financial results for the year ended December 31, 2007, and highlighted the corporate milestones achieved during the period.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

During 2007, the Company achieved the following corporate milestones:

Progress on Lead Candidate HspE7:

-- Made significant progress on the Company's Phase 1 cervical dysplasia

clinical trial examining the safety of new HspE7 leading to the recent

completion of enrollment and initial dosing of the last cohort in this

trial

-- Presented preclinical data at International Papillomavirus conference

demonstrating that co-administering HspE7 with certain adjuvants

promotes more potent responses than HspE7 alone

-- Demonstrated ability to elicit long-lasting tumor protection in vivo

suggesting that HspE7 may have utility in HPV-related diseases

-- Announced data from NCI-sponsored trial in cervical dysplasia showing

78 percent of patients achieved complete response or reduction of

lesion size by more than 50 percent

Corporate and Financial Achievements:

-- Strengthened the Management team with the addition of Richard Lai Fatt,

Ph.D., as Vice President of Corporate Development, and David Duncan,

Jr., as Vice President of Finance

-- Appointed Sandford D. Smith, President of the International Group and

Executive Vice President of Genzyme Corporation, to the Board of

Directors

-- Assembled a distinguished group of international experts for the

Company's Clinical and Scientific Advisory Board

'/>"/>
SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results ... Aviv Boim , CEO of Tikcro ... generate functional specific antibodies, targeting identified cancer immune checkpoints. ... by the development progress. We are excited to invest ... immune checkpoints gain clinical acceptance for cancer treatment."Net loss ...
(Date:5/27/2015)... BETHESDA, Md. , May 27, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for cancer, ... Chief Technical Officer of the Company, will be making ... Annual Meeting in Chicago on ... CDT, at the Industry Expert Theater in McCormick Place. ...
(Date:5/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... status of the Company,s Series A and Series ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March ... of Series A Preferred Stock and Series A-1 ...
(Date:5/26/2015)... Regenestem Network has announced the grand opening ... Argentina. The clinic will be lead by Silvina Pastrana, ... a multidisciplinary team of medical professionals who specialize in ... office. , The new Regenestem Network members plan ... in cellular therapies, and establish Regenestem protocols to isolate ...
Breaking Biology Technology:Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3
... Newly proposed Medicare rules designed to promote ... closely mirror quality reporting programs already well established ... MedeAnalytics analysis has found. (Logo: ... analysis is included in MedeAnalytics, white paper, "Accountable ...
... 4, 2011 Omeros Corporation (NASDAQ: OMER ... commercializing products focused on inflammation, bleeding and disorders of ... Demopulos, M.D., chairman and chief executive officer, is scheduled ... taking place in New York City this week.  The ...
... Techne Corporation (NASDAQ: TECH ) ... its R&D Systems subsidiary has acquired the assets ... manufacturer of innovative ubiquitin-related research products.  These products ... accelerate basic research and drug discovery efforts.  R&D ...
Cached Biology Technology:ACO Proposed Rule: Nine out of Ten Quality Measures Mirror Other Quality Reporting Programs 2Techne Corporation Announces Acquisition 2Techne Corporation Announces Acquisition 3Techne Corporation Announces Acquisition 4
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... Girls are hitting puberty earlier and earlier. One recent study ... some breast development by age 7. This news has upset ... cases for girls to develop faster, according to the authors ... a journal of the Association for Psychological Science. ...
... Here,s good news for anyone trying to lose weight or ... a weight loss drug that may revolutionize how we treat ... the September 2010 print issue of The FASEB Journal ... responsible for regulating body fat and bone mass. Then they ...
... that anchors itself to the sea bed, offers new clues ... Sheet a region that is thought to be vulnerable ... the Census of Antarctic Marine Life (CAML), scientists from British ... and deep sea regions around the continent and from further ...
Cached Biology News:Girls' early puberty linked to unstable environment via insecure attachment in infancy 2Scientists discover new protein that gets to the roots of obesity and osteoporosis 2Marine animals suggest evidence for a trans-Antarctic seaway 2
...
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
... Cap 0 (or Cap 0-like) RNA into ... has been shown to increase in vivo ... improvement is seen in Cap 0 structures ... as well as those Cap 0 structures ...
Biology Products: